Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • matt.berry01 matt.berry01 Dec 17, 2013 11:16 AM Flag

    Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab

    "Amgen (AMGN) today announced that the Phase 3 MENDEL-2 (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2) trial with evolocumab met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12 and the mean percent reduction from baseline in LDL-C at weeks 10 and 12."

    The study includes HoFH patients from AEGR's market.

    "The Phase 3 studies will evaluate evolocumab administered every two weeks and monthly in multiple patient populations, including in combination with statins in patients with ...[other populations mentioned here, ending with] ... homozygous (TESLA and TAUSSIG) familial hypercholesterolemia."
    http://finance.yahoo.com/news/amgen-announces-positive-top-line-141500332.html

 
AEGR
19.48-0.20(-1.02%)May 29 4:00 PMEDT